Loading...
Development and characterization of novel anti‐C5 monoclonal antibodies capable of inhibiting complement in multiple species
Over the last decade there has been an explosion in complement therapies; one‐third of the drugs in the clinic or in development target C5 protein. Eculizumab, a monoclonal antibody (mAb) that binds C5 and blocks its cleavage by the convertase, is the current reference standard treatment for atypica...
Na minha lista:
| Udgivet i: | Immunology |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6620185/ https://ncbi.nlm.nih.gov/pubmed/31120547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imm.13083 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|